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1,2-Xylosyltransferase Cxt1p Is Solely Responsible for Xylose Incorporation
into Cryptococcus neoformans Glycosphingolipids
Sherry A. Castle,1 Elizabeth A. Owuor,1 Stephanie H. Thompson,1 Michelle R. Garnsey,1
J. Stacey Klutts,2,3† Tamara L. Doering,2 and Steven B. Levery1*
Department of Chemistry, University of New Hampshire, G229 Parsons Hall, Durham, New Hampshire 03824-3598,1 and
Departments of Molecular Microbiology2 and Pathology and Immunology,3 Washington University School of Medicine,
St. Louis, Missouri 63110
Received 20 December 2007/Accepted 22 July 2008
The Man1,3(Xyl1,2)Man structural motif is common to both capsular polysaccharides of Cryptococcus
neoformans and to cryptococcal glycosphingolipids. Comparative analysis of glycosphingolipid structural pro-
files in wild-type and mutant strains showed that the Xyl1,2-transferase (Cxt1p) that participates in capsular
polysaccharide biosynthesis is also the sole transferase responsible for adding xylose to C. neoformans
glycosphingolipids.
The pathogenic basidiomycete Cryptococcus neoformans
causes serious disease in immunocompromised patients. A
dominant feature of C. neoformans is its polysaccharide cap-
sule, which is required for virulence. Xylose is a key compo-
nent of both of the major polysaccharides comprising the cap-
sule, glucuronoxylomannan (GXM) and galactoxylomannan
(GalXM), and is essential for proper capsule formation and
virulence (7, 16). Xylose is also a feature of C. neoformans
glycosylinositol phosphorylceramides (GIPCs) (9), glycosphin-
golipids characteristic of fungi (4, 12). Fungal GIPCs differ
fundamentally from mammalian glycosphingolipids in terms of
structure, and their biosynthesis is essential for normal growth
and life cycle (3, 5), suggesting they could be exploited for
diagnostic (18) and therapeutic strategies (6, 17, 19). Interest-
ingly, specific structural features are shared between the
GIPCs and the capsular polysaccharides of C. neoformans. The
GIPC core structure has the overall sequence Man3(Xyl2)
Man4Gal6Man2InsPCer (9). Like the structures of both
GXM and GalXM, this structure includes a branching Xyl1,2
residue linked to the reducing mannose of the Man1,3Man
motif. In a more extensive parallel to GalXM, the xylosylated
-mannose of the GIPC core is 1,4-linked to -galactose.
We have recently identified a cryptococcal Xyl1,2-trans-
ferase (Cxt1p) that acts in synthesizing both capsule polysac-
charides (11). Cells in which CXT1 has been deleted (cxt1::
 [10]) show a 30% reduction in 1,2-Xyl addition to GXM
and more than 90% reduction in 1,2-xylose addition to
GalXM (10). In light of the structural homologies mentioned
above, we tested the hypothesis that this enzyme also adds
xylose to GIPCs. To do this, we compared GIPCs from a
wild-type strain (JEC21) with those of the cxt1 mutant cells.
As a control, we used a strain which bears the deletion of
UXS1, the gene encoding UDP-GlcA decarboxylase (1, 16).
This strain (uxs1::ADE2) cannot synthesize the xylose donor
UDP-xylose and is therefore globally deficient in the xylose
modification of all glycoconjugates.
The C. neoformans JEC21, uxs1 (generously provided to
the Doering laboratory by Guilhem Janbon) (16), and cxt1
strains (10) were grown at 30°C with rotation (200 rpm). All of
these strains are closely related serotype D MAT strains: the
cxt1 strain was generated directly from JEC21, and the uxs1
strain was made from JEC155, which is derived from a related
serotype D MATa strain (JEC20). For lipid preparations, cells
were cultured in YPD medium (1% yeast extract, 2% Bacto
peptone, 2% glucose) for 3 days, collected by centrifugation
(6,000 rpm; 10 min; 4°C), washed once with cold water and
twice with cold 20 mM sodium azide, and frozen. The frozen
cell pellet (50 to 70 g [wet weight]) was then homogenized with
6 volumes of chloroform-methanol, 1:1 (vol/vol), and solvents
were evaporated. Enrichment of glycosphingolipids, recov-
* Corresponding author. Present address: Department of Molecular
and Cellular Medicine, University of Copenhagen, Blegdamsvej 3B,
Copenhagen, 2200 N, Denmark. Phone: 45 3532 7779. Fax: 45 3536
7980. E-mail: levery@imbg.ku.dk.
† Present address: University of Iowa Carver College of Medicine,
Iowa City, IA 52246.
 Published ahead of print on 1 August 2008.
FIG. 1. HPTLC profiles of GIPCs (orcinol-stained acidic lipid frac-
tions) from the C. neoformans strains indicated at the top of the lanes,
along with authentic Man2InsPCer (MIPC) standard from Aspergillus
fumigatus (lane S). WT, wild-type strain JEC21. The origin is indicated
by the line at the bottom of the image.
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FIG. 2. Mass spectrometry of GIPC fractions. (A and B) ESI-MS1 profiles (as [M(Na)Na] salt adducts) of crude GIPC fractions from the
uxs1 and cxt1 strains. (C) ESI-MS2 (m/z 1,586 3) spectrum of selected [M(Li)Li] salt adduct m/z 1,586 (Hex4InsPCer, corresponding to
the [M(Na)Na] salt adduct m/z 1,618 to 1632) in panel B. (D) ESI-MS3 (m/z 1,5863 9213) spectrum originating from the same molecular
species.
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ery of acidic fractions containing GIPCs by ion-exchange
chromatography, and purification of GIPCs by high-perfor-
mance liquid chromatography were then performed as de-
scribed previously (2, 18). Crude acidic fractions were analyzed by
high-performance thin-layer chromatography (HPTLC) on silica
gel no. 60 plates (E. Merck, Darmstadt, Germany) developed in
chloroform-methanol-water (60:40:9 [vol/vol/vol], containing
0.002% [wt/vol] CaCl2), with hexose-containing components
detected by Bial’s orcinol reagent.
Figure 1 shows the HPTLC profiles of GIPCs from the
wild-type, the uxs1, and the cxt1 cells. Each of the three
strains exhibits a pair of bands that comigrates with a fungal
Man2InsPCer (MIPC) standard; the differences in the rela-
tive distribution of the bands between monohydroxy (upper)
N-acyl forms and the dihydroxy (lower) N-acyl forms may re-
flect strain variation. (Consistent with this idea, the distribu-
tion of MIPC bands in the cxt1 strain is similar to that of the
bands in JEC21, its immediate parent strain [Fig. 1, lanes 3 and
1, respectively]; distribution in the uxs1 strain [Fig. 1, lane 2]
is somewhat altered.) Significantly, the wild-type cells also ex-
press major low-mobility components (Cn-5 and Cn-6) in a
darkly stained band that is completely absent from both the
cxt1 and the uxs1 cells. In contrast, the dominant product in
the cxt1 strain is a pair of higher-mobility components (Cn-4)
whose migration is consistent with that of compounds that are
less polar than those of the major wild-type species. The pat-
tern in the uxs1 strain, the control strain completely lacking
UDP-xylose, is nearly identical. While this work was in
progress, Gutierrez et al. (8) reported that the major GIPC
species in the uxs1 cells is a truncated compound, Man
3Man4Gal6Man2InsPCer. The production of the same
species in the cxt1 cells (Fig. 1) demonstrates that Cxt1p is
responsible for the transfer of all xylose to cryptococcal GIPCs.
We next performed structural studies to confirm the HPTLC
comigration and identities of dominant products from the
uxs1 and cxt1 strains. We first performed electrospray ion-
FIG. 3. Fragmentation of Man3Man4Gal6Man2InsPCer (Cn-4) in the modes ESI-MS2 and ESI-MS3.
TABLE 1. ESI-MS and ESI-MS2 data for cryptococcal GIPCsa
Strain and GIPC GIP t18:0/(fa) MW (u) M(H)
m/z
M(Na)Na	 M(Li)Li	 CerLi	 GIP(Li)Li	
WT (JEC21)
Cn-1 HexInsP 435
(h24:0) 1,087 1,132 1,100 690
(h224:0) 1,103 1,148 1,116 706
Cn-5 Hex4PenInsP 1,053
(h24:0) 1,705 1,750 1,718 690
(h224:0) 1,721 1,766 1,734 706
Cn-6 Hex5PenInsP 1,215
(h24:0) 1,867 1,912 1,880 690
(h224:0) 1,883 1,928 1,896 706
uxs1 and cxt1 mutants
Cn-1 HexInsP 435
(h24:0) 1,119 1,132 1,100 690
(h224:0) 1,135 1,148 1,116 706
Cn-4 Hex4InsP 921
(h24:0) 1,573 1,618 1,586 690
(h224:0) 1,589 1,634 1,602 706
a MW, molecular weight; M(H), protonated uncharged molecular species; WT, wild type.
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ization mass spectrometry (ESI-MS and ESI-MSn) to analyze
crude and purified GIPC fractions in the positive ion mode
(ESI), using a linear ion trap instrument (LTQ; Thermo
Finnigan, San Jose, CA). Results were interpreted essentially
as described in previous reports of purified GIPC components
(2, 13–15, 18). Molecular profiles of C. neoformans GIPCs as
[M(Na)Na] salt adducts were first acquired via ESI-MS.
The compositions of the major molecular species in the JEC21
profile (not shown) were consistent with those of HexInsPCer
(m/z 1,132, 1,148), Hex4PenInsPCer (m/z 1,750, 1,766), and
Hex5PenInsPCer (m/z 1,912, 1,928). These results correspond
to those of the previously characterized Man2InsPCer
(Cn-1), Man3(Xyl2)Man4Gal6Man2InsPCer (Cn-5),
and Man6Man3(Xyl2)Man4Gal6Man2InsPCer
(Cn-6) GIPC sequences (9). The m/z difference of 16 between
molecular adduct pair members is consistent with the differ-
ences between the degrees of hydroxylation of the ceramide
fatty-N-acyl group (t18:0 4-hydroxy-sphinganine with h24:0
and h224:0 fatty acids, respectively). These results show that
the low Rf band in the wild-type HPTLC profile (Fig. 1) cor-
responds to four components, Cn-5 and Cn-6, in an approxi-
mately 1:1 ratio, each bearing two types of ceramide. The
profile of JEC21, thus, differs somewhat from those of the
wild-type strains previously characterized (strain 444, which
expressed Cn-5 almost exclusively, and strain KN99, which
expressed Cn-6 almost exclusively [8, 9]).
The uxs1 and cxt1 mutant profiles are shown in Fig. 2A
and B. Both profiles exhibit pairs of [M(Na)Na] salt adduct
ions consistent with the HexInsPCer (m/z 1,132, 1,148) and
Hex4InsPCer (m/z 1,618, 1,634) compositions, corresponding
to previously characterized GIPC sequences Man2InsPCer
(Cn-1) and Man3Man4Gal6Man2InsPCer (Cn-4) (8).
We detected traces of components with intermediate numbers
of Hex residues in the mutant GIPC profiles, but no trace of
xylosylated GIPC products were detected in either mutant
profile. These results are summarized in Table 1.
To confirm the lack of xylose in mutant GIPC molecular
species, each molecular adduct in both profiles was selected for
further fragmentation by the ESI-MSn mode. To improve
fragmentation, we treated the samples with lithium iodide,
which converts GIPC molecular species to lithium salt adducts,
[M(Li)Li] (2, 13, 15, 18); this also reduces the m/z of each
molecular species by 32 compared with [M(Na)Na]
(Table 1). A ESI-MS2 spectrum acquired from the
[M(Li)Li] peak at m/z 1,586 (corresponding to the
[M(Na)Na]m/z 1,618) of the cxt1 mutant profile (Fig. 2C)
showed the predominant glycosylinositol phosphate (GIP)
fragment pair [B5PO3(Li)Li]
/[C5PO3(Li)Li]
 (m/z 921/
903, respectively) corresponding to Hex4InsP and other frag-
ments from glycosidic cleavages (Fig. 3; Table 2). A ceramide
ion ([Y0Li]
) was observable at m/z 690 (the h24:0/t18:0
lipoforms, not marked). An ESI-MS3 spectrum acquired
from the [C5PO3(Li)Li]
 ion at m/z 921 (m/z 1,5863 9213)
(Fig. 2D) showed that all of the glycosidic cleavages were
consistent with those of a linear Hex4InsP primary fragment
(Fig. 3; Table 2). Essentially identical spectra were acquired
from the [M(Li)Li] salt adduct at m/z 1,602 (corresponding
to the [M(Na)Na] m/z 1,634; not shown), except that the
ceramide ion was observed in the MS2 spectrum at m/z 706
(the h224:0/t18:0 lipoforms). Essentially identical results were
obtained from the corresponding pair of [M(Li)Li] salt
adducts in the uxs1 strain profile (not shown).
Our data show that the lack of a single xylosyltransferase,
Cxt1p, results in the complete absence of xylose from GIPCs of
cryptococcal cells. This loss of xylose yields glycolipids that are
indistinguishable from those formed in the uxs1 cells, where
no xylose can be added to any glycans. The absence of residual
xylose-containing GIPCs in the cxt1 mutant further indicates
that no other enzyme performs the function of xylose addition
during GIPC synthesis. In agreement with findings described
by Gutierrez et al. (8), we observed that the lack of xylose
modification of GIPC structures is accompanied by truncation
of the terminal mannose residues distal to the branch.
Using in vitro assays, we have found that Cxt1p transfers
xylose in 1,2 linkage to a Man3Man disaccharide (11); our
recent in vivo results further show that the cxt1 mutant is
partially deficient in the transfer of Xyl2 to both GXM and
GalXM (10). Together, these data and the current studies
demonstrate that Cxt1p is an unusual multiple-function xylo-
syltransferase that acts in three fundamental processes of C.
neoformans: GXM synthesis, GalXM synthesis, and GIPC syn-
thesis. The critical importance of the addition of xylose to
cryptococcal biology and virulence (7, 16) suggests that this
TABLE 2. Product ions formed in low-energy ESI-MS2 and
ESI-MS3 spectraa
m/z
Cn-4 assignment
h24:0 h224:0
1,586 1,602 M(Li)Li	
1,568 1,586 M(Li)Li
H2O	

1,424 1,440 M(Li)
HexLi	
1,262 1,278 M(Li)
2HexLi	
1,230 1,246 J(Li)Li
H2O	

1,100 1,116 M(Li)
3HexLi	
921 C5PO3(Li)Li	

903 B5PO3(Li)Li	

835 C5Li	

817 B5Li	

759 Y4/C5PO3(Li)Li	

741 Y4/B5PO3(Li)Li	

690 706 Y0Li	

673 Y4/C5Li	
 or C4Li	

672 Z0Li	

655 Y4/B5Li	
 or B4Li	

597 Y3/C5PO3(Li)Li	

579 Y3/B5PO3(Li)Li	

511 Y3/C5Li	
 or Y4/C4Li	

or C3Li	

493 Y3/B5Li	
 or Z3/C5Li	

or Y4/B4Li	
 or Z4/
C4Li	
 or B3Li	

435 Y2/C5PO3(Li)Li	

417 Y2/B5PO3(Li)Li	

349 C2Li	
 or any equivalent
two-residue segment
331 C2Li	
 or any equivalent
two-residue segment
a Data show m/z of product ions formed in low-energy ESI-MS2 and ESI-MS3
spectra of lithium adducts of tetraglycosylinositol phosphorylceramide from C.
neoformans GIPC (Cn-4). Base peaks are in boldface type, and fragment desig-
nations are shown as in references 2, 13, 15 and 18 and in Fig. 3.
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fungus-specific protein warrants further investigation, in par-
ticular with respect to its role in cryptococcal pathogenesis.
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